United States Non-PVC IV Bags Market Forecast to Reach $2.04 Billion by 2031 | Single-Chambered IV Bags Expected to Dominate with 60% Share

Market Size & Growth

The global Non-PVC IV Bags Market reached USD 1.23 billion in 2024 and is projected to grow to USD 2.04 billion by 2031, expanding at a CAGR of 6.8% during the forecast period 2025-2032. Growth is driven by increasing adoption of PVC-free medical devices, rising patient safety awareness, and expansion of healthcare infrastructure across North America, Europe, and Asia-Pacific. These IV bags are primarily used in blood transfusions, parenteral nutrition, and drug administration, offering chemical stability, low leachables, and improved patient safety. Non-PVC IV bags are intravenous fluid containers manufactured from alternative materials such as polyethylene (PE), polypropylene (PP), and ethylene-vinyl acetate (EVA), designed to reduce health risks associated with PVC and DEHP leaching, while ensuring compatibility with diverse medical applications.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/non-pvc-iv-bags-market?Juli

Recent Developments:

United States
✅ October 2025: Baxter launched single-chambered EVA IV bags with improved chemical stability and reduced environmental impact.

✅ August 2025: B. Braun Melsungen AG expanded its polyethylene IV bag production to meet rising U.S. hospital demand.

✅ May 2025: Pfizer, Inc. introduced pre-filled non-PVC IV bags for critical care drug administration.

Global
✅ September 2025: PolyCine GmbH launched multi-chambered IV bags in Europe for sequential drug delivery.

✅ June 2025: RENOLIT expanded its EVA IV bag portfolio across Asia-Pacific.

✅ March 2025: Angiplast Pvt. Ltd. entered Latin America with cost-effective non-PVC IV bags for hospitals and clinics.

Mergers & Acquisitions:

United States
✅ July 2025: Baxter acquired a specialty IV bag manufacturer to expand its EVA-based product line.

Europe & Asia-Pacific
✅ February 2025: RENOLIT formed a partnership with a European distributor to enhance market penetration.

✅ January 2025: Jiangxi SanxinMedtec Co., Ltd. merged with Shanghai Xin Gen Eco-Technologies Co., Ltd., strengthening production and distribution capabilities in Asia-Pacific.

Key Players:
Baxter | Angiplast Pvt. Ltd. | PolyCine GmbH | RENOLIT | Kraton Corp. | B. Braun Melsungen AG | Pfizer, Inc. | Shanghai Xin Gen Eco-Technologies Co., Ltd. | Jiangxi SanxinMedtec Co., Ltd.

Key Highlights:
Baxter - Leader in single- and multi-chambered EVA and polyethylene IV bags with focus on chemical stability and hospital adoption.

Angiplast Pvt. Ltd. - Cost-effective non-PVC IV bag solutions, expanding in emerging markets including Latin America.

PolyCine GmbH - Specializes in multi-chambered IV bags for sequential drug delivery in European markets.

RENOLIT - Expands EVA IV bag portfolio across Asia-Pacific, focusing on high-quality material and industrial supply chains.

Kraton Corp. - Supplies specialty polymer materials for non-PVC IV bag manufacturing, enabling flexibility and chemical resistance.

B. Braun Melsungen AG - Produces polyethylene IV bags with scalable manufacturing for U.S. and European hospitals.

Pfizer, Inc. - Pre-filled non-PVC IV bags for critical care drug administration, enhancing operational efficiency in healthcare.

Shanghai Xin Gen Eco-Technologies Co., Ltd. - Advanced non-PVC IV bag production for Asia-Pacific hospitals and clinics.

Jiangxi SanxinMedtec Co., Ltd. - Strengthened production and distribution through merger, serving hospitals and clinical centers in Asia-Pacific.

Market Segmentation:

➥ By type, single-chambered IV bags dominate with a 60% share, preferred for ease of use and general IV therapy, while multi-chambered bags account for 40%, widely used for complex formulations and sequential drug delivery.

➥By material, polyethylene IV bags hold 35%, valued for their chemical stability and environmental safety; polypropylene (PP) IV bags represent 25%, offering durability and temperature resistance; ethylene-vinyl acetate (EVA) IV bags contribute 30%, known for flexibility, low leachables, and compatibility with sensitive drugs; other specialty materials account for 10%, catering to niche applications.

➥By content, frozen mixtures occupy 45%, primarily for blood storage and parenteral nutrition, whereas liquid mixtures dominate with 55%, used extensively in general IV therapy and drug delivery.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=non-pvc-iv-bags-market?Juli

Regional Insights:

North America leads with a 40% share (USD 492 million, 2024), driven by advanced healthcare infrastructure, high adoption of EVA and polyethylene IV bags, and strong regulatory support for PVC-free medical devices.

Europe holds 30% (USD 369 million, 2024), fueled by EU regulations on PVC medical devices, a rising geriatric population, and increased hospital investments in safe IV solutions.

Asia-Pacific accounts for 20% (USD 246 million, 2024; CAGR 7.5%), with growth supported by expanding hospital networks, rising awareness of PVC-free medical products, and adoption of advanced IV bag technologies in China, India, and Japan.

Latin America, Middle East & Africa collectively represent 10% (USD 123 million, 2024), driven by healthcare modernization, expansion of hospital infrastructure, and increasing preference for eco-friendly medical products.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/non-pvc-iv-bags-market?Juli

Market Dynamics:

Drivers:
Rising demand for safer, non-PVC IV bags due to health concerns associated with DEHP. Expanding hospital infrastructure and increasing adoption of advanced IV therapies. Growing awareness among patients and clinicians regarding eco-friendly and sustainable alternatives.

Restraints:
Higher production costs compared to conventional PVC-based IV bags.
Technical complexity in manufacturing multi-chambered and specialty IV bags.
Limited availability of high-quality EVA and polypropylene (PP) materials in certain regions.

Opportunities:
Expansion in emerging markets with developing hospital and clinical infrastructure. Development of multi-chambered and pre-filled IV bags for specialty drug administration.Integration with hospital digital supply chains and automated IV delivery systems. Focus on recyclable and sustainable packaging solutions to comply with environmental regulations.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.